Gerresheimer's Fate Hangs on a June Deadline and Creditor Talks

German pharma packager Gerresheimer faces a severe crisis with an accounting scandal, BaFin probe, credit default, and SDAX expulsion, while some investors bet on a turnaround.

The German pharmaceutical packaging specialist Gerresheimer is navigating a severe corporate crisis with its financial reporting grounded. The absence of an audited annual report has triggered a chain reaction, from regulatory probes and an index expulsion to a scramble for liquidity, all while a handful of institutional investors place a contrarian bet on the beleaguered stock.

At the heart of the turmoil is an accounting scandal. The German financial regulator, BaFin, has been scrutinizing the company's consolidated financial statements since September 2025. The investigation has now widened to include the 2025 half-year report, specifically examining whether a 196.5 million euro impairment in the Advanced Technologies segment should have been booked earlier. The fallout has also ensnared the company's auditor, KPMG. Germany's audit oversight body, APAS, has initiated professional misconduct proceedings against the firm. The allegation is that KPMG issued an unqualified audit opinion for the 2024 accounts despite the presence of non-compliant "bill-and-hold" agreements. These faulty bookings amounted to 35 million euros in revenue and 24 million euros in adjusted EBITDA.

The reporting vacuum has paralyzed the company's financial calendar. There are no fixed dates for the Q1 report or the annual general meeting, and the audited 2025 financial statements have been postponed until June 2026. This breach of contractual reporting obligations has placed Gerresheimer in technical default on its credit lines. Management is currently in negotiations with lenders to secure extensions and avoid a termination of facilities.

To shore up its balance sheet, the company has initiated a sale process for its US subsidiary, Centor. Morgan Stanley is seeking buyers for the drug packaging segment, which was last valued at 292 million euros. This move is accompanied by the planned closure of the Chicago Heights plant by the end of 2026.

The crisis culminated in the company's expected expulsion from the SDAX small-cap index after it missed a key reporting deadline. The stock has suffered dramatically, losing approximately 68.47 percent over the past twelve months. On the last trading day detailed, shares closed at a meager 17.17 euros.

Despite the profound uncertainty, some large investors see an opportunity. The CastleKnight Master Fund and Deka Investment have reported new stakes built at the depressed price level, positioning themselves against active short-sellers. Meanwhile, the shareholder protection association DSW is preparing damage claims against former CEO Dietmar Siemssen and ex-CFO Bernd Metzner based on an expert report.

All forward guidance is now conditional. Gerresheimer's revenue forecast of 2.3 to 2.4 billion euros for 2026 is explicitly tied to the outcome of the credit negotiations and the BaFin investigation. The audited financial statements targeted for June 2026 represent the most urgent milestone. Success there, coupled with secured financing, could lay a foundation for stabilization. Failure would risk further escalation with both regulators and credit markets. The subsequent test will be the half-year report scheduled for July 14, 2026, which must present solid numbers and signed loan agreements to prevent another wave of distrust.